Unstable angina: the first 48 hours and later in-hospital management.
Unstable angina is a common cardiovascular condition associated with major adverse clinical events. Over the last 15 years, therapeutic advances have dramatically reduced the complication and mortality rates of this serious condition. The standard of therapy in patients with unstable angina now incorporates the combined use of potent antithrombotic (aspirin, clopidogrel, heparin and glycoprotein IIb/IIIa receptor antagonists) and anti-anginal (beta-blockade and intravenous nitrates) regimens complemented by the selective and judicious application of coronary revascularisation strategies. Increasingly, these invasive and non-invasive therapeutic interventions are being guided not only by the clinical risk profile but also by the determination of serum cardiac and inflammatory markers. Moreover, rapid and intensive management of associated risk factors, such as hypercholesterolaemia, would appear to have potentially substantial benefits even within the acute in-hospital phase of unstable angina.
Newby
D E
DE
Department of Cardiology, Edinburgh Royal Infirmary, Edinburgh, UK.
Fox
K A
KA
D000368:Aged; D000789:Angina, Unstable / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D002097:C-Reactive Protein / Q000032:analysis; D001026:Coronary Artery Bypass; D023903:Coronary Restenosis / Q000517:prevention & control; D004562:Electrocardiography; D004638:Emergency Treatment; D006760:Hospitalization; D006801:Humans; D008875:Middle Aged; D009204:Myocardial Revascularization; D015221:Potassium Channels / Q000187:drug effects; D018570:Risk Assessment; D013997:Time Factors; D014336:Troponin / Q000097:blood
D015221:Potassium Channels; D014336:Troponin; D002097:C-Reactive Protein